Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants orphan drug status to IMM-101 for pancreatic cancer

Sep. 26, 2014

FDA grants orphan drug designation to MabVax Therapeutics' neuroblastoma vaccine

Sep. 26, 2014

Amgen submits BLA for BiTE immunotherapy blinatumomab

Sep. 23, 2014

Kancera updates on drugs and vaccines targeting ROR1

Sep. 23, 2014

TapImmune reports interim data from phase I trial of folate receptor alpha antigens

Sep. 18, 2014

DCVax-L is the first drug to be designated by U.K. authorities as a PIM

Sep. 17, 2014

Lilly reports phase III RAISE trial meets primary endpoint of overall survival

Sep. 16, 2014

Asterias Biotherapeutics partners with Cancer Research UK on AST-VAC2 study

Sep. 16, 2014

Merck Serono discontinues development of tecemotide as a monotherapy in NSCLC

Sep. 15, 2014

Enrollment open in pivotal study of MGN-1703 for metastatic colorectal carcinoma

Sep. 15, 2014

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...